Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.
Since 2016 drug developers have spent $23.6bn in-licensing cancer projects, almost half of the sector’s up-front bill.
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?
The group’s restructuring, C-suite clearout and refocusing on bemarituzumab is rewarded with a $1.9bn buyout by Amgen.